Jan 15 (Reuters) - The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration ...

A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...

Dr. Martin Makary testifies during his confirmation hearing before the Senate Committee on Health, Education, Labor, and Pensions Committee on March 06, 2025, in Washington, DC. This story was ...

FDA delays drug reviews for two priority voucher drugs amid safety and efficacy concerns, extending timelines for Sanofi and Disc Medicine products.

WASHINGTON (AP) — U.S. regulators will begin offering faster reviews to new medicines that administration officials deem as promoting “the health interests of Americans,” under a new initiative ...

Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

Geriatrics and Aging. 2005;8(6):43-45. Is the treatment still indicated or has the diagnosis been refuted? For example, a putative diagnosis of angina may have subsequently been disproved. Treatments ...

People with type 2 diabetes who receive comprehensive medication reviews (CMRs) had better adherence with oral antidiabetic drugs and statin utilization compared to those who did not receive CMRs, a ...

A study found that clinical pharmacist-led reviews of hospital medications for older adults with hip fractures were linked to significantly lower rates of adverse drug reactions (ADRs). The research, ...

U.S. regulators will begin offering faster reviews to new medicines that administration officials deem as promoting “the health interests of Americans,” under a new initiative announced Tuesday. Food ...